Sleep apnea involves more than snoring

Sleep apnea is a condition where breathing repeatedly stops during sleep, leading to low oxygen levels and extreme tiredness. It is commonly associated with being overweight, as excess tissue can block the airway.

New drug offers weight loss solution

A new drug called retatrutide shows promise in treating sleep apnea by promoting weight loss. This could address the root cause of the condition in many patients, offering an alternative to traditional treatments.

Study published in top medical journal

An international study led by Ronald Grunstein was published in the New England Journal of Medicine in October 2026. It showed that a weekly injection of retatrutide significantly reduced sleep apnea symptoms in overweight adults.

Traditional treatment has limitations

The standard treatment for sleep apnea is a CPAP machine that delivers air pressure to keep the airway open. However, many patients find it uncomfortable or difficult to use consistently.

Trials tested drug on different groups

Researchers conducted two phase 3 trials, one with non-diabetic patients and the other with diabetics. Overweight adults with at least 15 breathing pauses per hour received weekly injections of varying doses or a placebo over 80 weeks.

Drug significantly reduced breathing pauses

After 80 weeks, all doses of retatrutide reduced sleep apnea more than the placebo. The two highest doses reduced the average number of breathing pauses by about 40%, potentially moving many patients to a milder form of the disease.

Unique mechanism of action

Retatrutide activates three hormonal receptors simultaneously, unlike other drugs such as semaglutide, which targets only one, and tirzepatide, which targets two. It mimics intestinal hormones like GLP-1, which help regulate appetite and metabolism.